Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
Earnings for Chinook Therapeutics, Inc. (KDNY)
Earnings in 2022 (TTM): $-180,274,000
According to Chinook Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-180,274,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Chinook Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-180,274,000 | $-184,615,000 |
| 2021 | $-99,208,000 | $-101,301,000 |
| 2020 | $-83,625,000 | $-81,622,000 |
| 2019 | $-46,519,000 | $-46,851,000 |
| 2018 | $-96,140,000 | $-95,357,000 |
| 2017 | $-103,227,000 | $-91,863,000 |
| 2016 | $-69,684,000 | $-91,148,000 |
| 2015 | $-39,308,000 | $-39,209,000 |